Loading...

IDYA IDEAYA BIOSCIENCES INC Operational Disruptions 8-K Filing

DY B

DY

IDEAYA BIOSCIENCES INC

(IDYA)

2024 8-K

Show Summary

Summary

Financial Results

Management Change

License Agreement

Q3 Financial Results

Clinical Update

Presentation Announcement

Clinical Trial Update

Financial Results Announcement

Agreement with Biocytogen P...

Underwriting Agreement

Financial Update

Clinical Update

Resignation of Officer

Clinical Updates

Annual Meeting of Stockholders

Financial Results Announcement

Agreement with MSD Internat...

Financial Results Announcement

Open Market Sales Agreement

Collaboration Agreement

Lease Agreement

Earnings Reports

Underwriting Agreement

Financial Update

Clinical Updates

Resignation of CFO

Earnings Report

Open Market Sales Agreement

Annual Meeting and Compensa...

Lease Agreement for New Fac...

Amendment to Clinical Trial...

Financial Results Announcement

Underwriting Agreement

Financial Update

Clinical Updates

Financial Results Announcement

External Links:

Ideaya Biosciences announced clinical data from their Phase 2 trial of darovasertib for neoadjuvant/adjuvant treatment in uveal melanoma, showing positive results and manageable adverse events.

AI Assistant

IDEAYA BIOSCIENCES INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.